XNAS · Healthcare · Biotechnology
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | Q1 2026 | -0.98 | -0.91 | +7.14% | $31.7M | ✅ Beat | +0.37% | +13.14% | — |
| 2026-02-24 | Q4 2025 | -1.12 | -0.10 | +91.07% | $114.1M | ✅ Beat | +0.74% | -15.70% | -26.85% |
| 2025-11-04 |
| Q3 2025 |
| -1.01 |
| -1.10 |
| -8.91% |
| $9.7M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -1.07 | -1.00 | +6.54% | $8.5M | ✅ Beat | +0.21% | -9.84% | -0.86% |
| 2025-05-06 | Q1 2025 | -1.17 | -1.24 | -5.98% | $7.5M | ❌ Miss | — | — | — |
| 2025-02-25 | Q4 2024 | -1.28 | -1.09 | +14.84% | $30.1M | ✅ Beat | — | — | — |
| 2024-11-05 | Q3 2024 | -1.16 | -1.17 | -0.86% | $14.3M | ❌ Miss | — | — | — |
| 2024-08-06 | Q2 2024 | -1.14 | -1.11 | +2.63% | $11.8M | ✅ Beat | — | — | — |
Showing last 8 quarters.